Late last week, the FDA ... approved cell therapy – and the first without direct competition in the market. Tecartus will launch with a $373,000 list price, around the same as Gilead/Kite's ...
Bristol-Myers Squibb finally has FDA approval ... Kite therapies – Yescarta (axicabtagene ciloleucel) and Tecartus (brexucabtagene autoleucel) – and is BMS’ first cell therapy product.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback